Mountain Manor Treatment Center/Maryland Treatment Centers, Baltimore, Maryland; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mountain Manor Treatment Center/Maryland Treatment Centers, Baltimore, Maryland.
J Adolesc Health. 2020 Dec;67(6):778-785. doi: 10.1016/j.jadohealth.2020.07.038. Epub 2020 Aug 29.
Young adults are disproportionately affected by the current opioid crisis. Although medications for opioid use disorder are broadly effective, with reductions in morbidity and mortality, the particular effectiveness of medications for opioid use disorder among young adults is less well understood.
This secondary analysis compared young adults (aged 18-25 years) with older adults (aged ≥26 years) in a large comparative effectiveness trial ("XBOT") that randomized subjects to extended-release naltrexone or sublingual buprenorphine-naloxone for 6 months. Opioid relapse was defined by opioid use over four consecutive weeks or seven consecutive days, using urine testing and self-report.
Among subjects in the intention-to-treat sample (n = 570, all randomized participants), a main effect of age group was found, with higher relapse rates among young adults (70.3%) compared with older adults (58.2%), with an odds ratio of 1.72 (95% confidence interval = 1.08-2.70), p = .02. In the per-protocol sample (n = 474, only participants who started medication), relapse rates were higher among young adults (66.3%) compared with older adults (50.8%), with an odds ratio of 1.91 (95% confidence interval = 1.19-3.06). Among the intention-to-treat sample, survival analysis revealed a significant time-by-age group interaction (p = .01) with more relapse over time in young adults. No significant interactions between age and medication group were detected.
Young adults have increased rates of relapse compared with older adults, perhaps because of vulnerabilities that increase their risk for treatment dropout and medication nonadherence, regardless of medication assignment. These results suggest that specialized, developmentally informed interventions may be needed to improve retention and successful treatment of opioid use disorder among young adults.
年轻人受到当前阿片类药物危机的不成比例的影响。尽管阿片类药物使用障碍的药物治疗在降低发病率和死亡率方面广泛有效,但在年轻人中使用阿片类药物使用障碍药物的特殊效果了解较少。
这项二次分析比较了一项大型比较效果试验(“XBOT”)中的年轻人(18-25 岁)和老年人(≥26 岁),该试验将受试者随机分配至长效纳曲酮或舌下丁丙诺啡-纳洛酮治疗 6 个月。阿片类药物复发的定义是连续四周或七天连续使用阿片类药物,使用尿液检测和自我报告。
在意向治疗样本(n=570,所有随机参与者)中,发现年龄组存在主要影响,年轻人(70.3%)的复发率高于老年人(58.2%),优势比为 1.72(95%置信区间=1.08-2.70),p=0.02。在符合方案样本(n=474,仅开始服用药物的参与者)中,年轻人(66.3%)的复发率高于老年人(50.8%),优势比为 1.91(95%置信区间=1.19-3.06)。在意向治疗样本中,生存分析显示时间与年龄组之间存在显著的交互作用(p=0.01),年轻人的复发率随时间增加。未检测到年龄和药物组之间的显著相互作用。
与老年人相比,年轻人的复发率更高,这可能是由于他们面临的脆弱性增加了治疗中断和药物不依从的风险,而与药物分配无关。这些结果表明,可能需要专门的、与发育相关的干预措施,以提高年轻人对阿片类药物使用障碍的保留率和成功治疗。